Published in PLoS Biol on May 06, 2008
Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet (2010) 9.53
Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer (2010) 8.55
Beyond GWASs: illuminating the dark road from association to function. Am J Hum Genet (2013) 2.67
FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet (2009) 2.62
Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell (2013) 2.56
Genetic susceptibility to breast cancer. Mol Oncol (2010) 2.52
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Architecture of inherited susceptibility to common cancer. Nat Rev Cancer (2010) 2.14
Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis (2008) 2.03
Evaluation of 11 breast cancer susceptibility loci in African-American women. Cancer Epidemiol Biomarkers Prev (2009) 1.90
Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet (2008) 1.82
A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell (2013) 1.75
Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res (2008) 1.72
FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women. Carcinogenesis (2010) 1.63
A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression. PLoS Genet (2011) 1.60
Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med (2011) 1.51
Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.46
A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol (2010) 1.46
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet (2010) 1.40
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet (2013) 1.39
Analytical methods for inferring functional effects of single base pair substitutions in human cancers. Hum Genet (2009) 1.39
CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med (2009) 1.38
Genic and nongenic contributions to natural variation of quantitative traits in maize. Genome Res (2012) 1.26
Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C. Genome Res (2014) 1.26
Extent of differential allelic expression of candidate breast cancer genes is similar in blood and breast. Breast Cancer Res (2009) 1.16
Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet (2009) 1.13
Master regulators of FGFR2 signalling and breast cancer risk. Nat Commun (2013) 1.12
A genome-wide association study of breast cancer in women of African ancestry. Hum Genet (2012) 1.11
Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10. Breast Cancer Res (2011) 1.09
Mammary gland growth factors: roles in normal development and in cancer. Cold Spring Harb Perspect Biol (2010) 1.08
Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res (2010) 1.07
Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.07
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer (2013) 1.06
NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations. Mol Cancer (2010) 1.06
Systematic detection of putative tumor suppressor genes through the combined use of exome and transcriptome sequencing. Genome Biol (2010) 1.01
Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. Mol Endocrinol (2009) 1.00
Hereditary breast cancer: ever more pieces to the polygenic puzzle. Hered Cancer Clin Pract (2013) 0.99
Polygenic susceptibility to breast cancer: current state-of-the-art. Future Oncol (2009) 0.98
An insulator loop resides between the synthetically interacting elements of the human/rat conserved breast cancer susceptibility locus MCS5A/Mcs5a. Nucleic Acids Res (2011) 0.97
Fibroblast growth factor receptor signaling is essential for normal mammary gland development and stem cell function. Stem Cells (2013) 0.97
FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. Br J Cancer (2014) 0.96
Simultaneous SNP identification and assessment of allele-specific bias from ChIP-seq data. BMC Genet (2012) 0.96
Identification of Novel Susceptibility Genes for Breast Cancer - Genome-Wide Association Studies or Evaluation of Candidate Genes? Breast Care (Basel) (2009) 0.96
Role of heparan sulfatases in ovarian and breast cancer. Am J Cancer Res (2013) 0.95
Low-risk susceptibility alleles in 40 human breast cancer cell lines. BMC Cancer (2009) 0.94
eQTL Mapping Using RNA-seq Data. Stat Biosci (2013) 0.93
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat (2015) 0.93
Novel breast cancer risk alleles and endometrial cancer risk. Int J Cancer (2008) 0.93
Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesis. J Cell Mol Med (2008) 0.93
Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study. Breast Cancer Res (2011) 0.92
Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget (2016) 0.90
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol (2014) 0.90
Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer. Breast Cancer Res (2012) 0.90
FGF-2, TGFbeta-1, PDGF-A and respective receptors expression in pleomorphic adenoma myoepithelial cells: an in vivo and in vitro study. J Appl Oral Sci (2010) 0.90
FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells. PLoS One (2013) 0.89
Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. Breast Cancer Res (2012) 0.88
rs2981582 is associated with FGFR2 expression in normal breast. Cancer Genet Cytogenet (2010) 0.88
Retracted Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer. Am J Pathol (2010) 0.87
Genome-wide association study of breast cancer in the Japanese population. PLoS One (2013) 0.87
Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. Am J Hum Genet (2016) 0.87
Deconvoluting complex tissues for expression quantitative trait locus-based analyses. Philos Trans R Soc Lond B Biol Sci (2013) 0.87
FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype. BMC Res Notes (2011) 0.87
FGF ligands of the postnatal mammary stroma regulate distinct aspects of epithelial morphogenesis. Development (2014) 0.87
Activating somatic FGFR2 mutations in breast cancer. PLoS One (2013) 0.86
An integrative genomics approach to biomarker discovery in breast cancer. Cancer Inform (2011) 0.86
ASEQ: fast allele-specific studies from next-generation sequencing data. BMC Med Genomics (2015) 0.86
Association of FGFR2 gene polymorphisms with the risk of breast cancer in population of West Siberia. Eur J Hum Genet (2009) 0.85
Targeting RTK Signaling Pathways in Cancer. Cancers (Basel) (2015) 0.85
Genetic variants of fibroblast growth factor receptor 2 (FGFR2) are associated with breast cancer risk in Chinese women of the Han nationality. Immunogenetics (2011) 0.85
The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF-κB signaling. Mol Cell Biol (2012) 0.84
Identifying breast cancer risk loci by global differential allele-specific expression (DASE) analysis in mammary epithelial transcriptome. BMC Genomics (2012) 0.84
Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancer. Cancer Sci (2014) 0.84
Germline allele-specific expression of DAPK1 in chronic lymphocytic leukemia. PLoS One (2013) 0.83
Acute ethanol alters multiple histone modifications at model gene promoters in the cerebral cortex. Alcohol Clin Exp Res (2014) 0.83
Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer. PLoS One (2010) 0.83
Negative regulation of fibroblast growth factor 10 (FGF-10) by polyoma enhancer activator 3 (PEA3). Eur J Cell Biol (2009) 0.83
Relation of FGFR2 genetic polymorphisms to the association between oral contraceptive use and the risk of breast cancer in Chinese women. Am J Epidemiol (2011) 0.83
Retracted Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer. Am J Pathol (2010) 0.82
Partitioning transcript variation in Drosophila: abundance, isoforms, and alleles. G3 (Bethesda) (2011) 0.81
Common low-penetrance risk variants associated with breast cancer in Polish women. BMC Cancer (2013) 0.81
Environment and genetics: Making sense of the noise. Nature (2012) 0.81
Integrative Analysis of Response to Tamoxifen Treatment in ER-Positive Breast Cancer Using GWAS Information and Transcription Profiling. Breast Cancer (Auckl) (2012) 0.81
The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects. Hum Mol Genet (2009) 0.81
Heterogeneity of Breast Cancer Associations with Common Genetic Variants in FGFR2 according to the Intrinsic Subtypes in Southern Han Chinese Women. Biomed Res Int (2015) 0.80
Recommendations for Accurate Resolution of Gene and Isoform Allele-Specific Expression in RNA-Seq Data. PLoS One (2015) 0.80
Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study. BMC Cancer (2009) 0.80
A study on genetic variants of Fibroblast growth factor receptor 2 (FGFR2) and the risk of breast cancer from North India. PLoS One (2014) 0.80
Case-control study on the fibroblast growth factor receptor 2 gene polymorphisms associated with breast cancer in chinese han women. J Breast Cancer (2013) 0.79
Data analysis issues for allele-specific expression using Illumina's GoldenGate assay. BMC Bioinformatics (2010) 0.79
The gene desert mammary carcinoma susceptibility locus Mcs1a regulates Nr2f1 modifying mammary epithelial cell differentiation and proliferation. PLoS Genet (2013) 0.79
FOXA1 and breast cancer risk. Nat Genet (2012) 0.79
Integrative genomic analysis for the discovery of biomarkers in prostate cancer. Biomark Insights (2014) 0.78
Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province. Oncotarget (2015) 0.78
Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study. Menopause (2013) 0.78
Common polymorphisms in angiogenesis. Cold Spring Harb Perspect Med (2012) 0.78
FGFR2 risk SNPs confer breast cancer risk by augmenting oestrogen responsiveness. Carcinogenesis (2016) 0.78
The FGF/FGFR axis as a therapeutic target in breast cancer. Expert Rev Endocrinol Metab (2013) 0.77
Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. Am J Hum Genet (2016) 0.77
Using LASSO regression to detect predictive aggregate effects in genetic studies. BMC Proc (2011) 0.77
Modulation of fibroblast growth factor signaling is essential for mammary epithelial morphogenesis. PLoS One (2014) 0.77
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Genome-wide analysis of estrogen receptor binding sites. Nat Genet (2006) 18.63
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 10.74
A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J (1990) 9.17
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev (2005) 3.91
A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene (2006) 3.21
CCAAT/enhancer-binding proteins (C/EBP) beta and delta activate osteocalcin gene transcription and synergize with Runx2 at the C/EBP element to regulate bone-specific expression. J Biol Chem (2001) 2.27
MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat Genet (2007) 2.14
Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer (1992) 2.10
Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res (2006) 2.03
The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem (2002) 1.66
Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene (1997) 1.63
Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Oncogene (2004) 1.44
The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem (2003) 1.39
Expression of keratinocyte growth factor and its receptor in human breast cancer: its inhibitory role in the induction of apoptosis possibly through the overexpression of Bcl-2. Arch Histol Cytol (2004) 1.32
Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res (2000) 1.23
A role for fibroblast growth factor receptor-2 in the altered osteoblast phenotype induced by Twist haploinsufficiency in the Saethre-Chotzen syndrome. Hum Mol Genet (2005) 1.19
Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer. Lab Invest (2004) 1.17
Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors. Breast Cancer Res (2000) 1.16
Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein. Mol Cell Biol (2005) 1.03
Activation of the immunoglobulin kappa 3' enhancer in pre-B cells correlates with the suppression of a nuclear factor binding to a sequence flanking the active core. Nucleic Acids Res (1994) 1.00
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Signatures of mutational processes in human cancer. Nature (2013) 21.63
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
International network of cancer genome projects. Nature (2010) 20.35
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med (2008) 9.64
Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet (2002) 8.89
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst (2008) 5.82
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol (2005) 5.63
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res (2007) 5.62
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer (2007) 4.06
Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol (2008) 3.73
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70
Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer (2004) 3.64
Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst (2004) 3.53
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
MicroRNA: implications for cancer. Virchows Arch (2007) 3.17
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
p300/CBP and cancer. Oncogene (2004) 3.13
The implications of clonal genome evolution for cancer medicine. N Engl J Med (2013) 2.78
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping. Cancer Genet Cytogenet (2005) 2.70
Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst (2004) 2.66
FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet (2009) 2.62
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet (2002) 2.57
Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci Transl Med (2012) 2.55
Sizing up miRNAs as cancer genes. Nat Med (2005) 2.48
Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer (2011) 2.42
A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology (2003) 2.39
Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep (2013) 2.37
Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med Genomics (2010) 2.34
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med (2013) 2.34
Telomere length in prospective and retrospective cancer case-control studies. Cancer Res (2010) 2.30
An evaluation of analysis pipelines for DNA methylation profiling using the Illumina HumanMethylation450 BeadChip platform. Epigenetics (2013) 2.28
Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet (2007) 2.27
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res (2014) 2.25
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
The shaping and functional consequences of the microRNA landscape in breast cancer. Nature (2013) 2.22
A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res (2003) 2.21
ChAMP: 450k Chip Analysis Methylation Pipeline. Bioinformatics (2013) 2.21
Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland. Breast Cancer Res (2012) 2.18
A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol (2006) 2.17
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res (2006) 2.16
PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer. Bioinformatics (2006) 2.12
Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer (2008) 2.11
A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res (2008) 2.09
ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med (2011) 2.07
A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene (2005) 2.05
Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. Hum Mol Genet (2005) 2.05
The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell (2007) 2.05
Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet (2002) 2.04
Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res (2005) 2.03
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol (2010) 2.01
Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer. Genome Res (2012) 1.95
Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res (2002) 1.95
Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the FTO type 2 diabetes and obesity susceptibility locus. PLoS One (2010) 1.93
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2007) 1.92
Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer (2011) 1.81